<SEC-DOCUMENT>0001279569-19-001074.txt : 20190507
<SEC-HEADER>0001279569-19-001074.hdr.sgml : 20190507
<ACCEPTANCE-DATETIME>20190507140654
ACCESSION NUMBER:		0001279569-19-001074
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20190507
FILED AS OF DATE:		20190507
DATE AS OF CHANGE:		20190507

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Canopy Growth Corp
		CENTRAL INDEX KEY:			0001737927
		STANDARD INDUSTRIAL CLASSIFICATION:	MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A6
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38496
		FILM NUMBER:		19802460

	BUSINESS ADDRESS:	
		STREET 1:		1 HERSHEY DRIVE
		CITY:			SMITH FALLS
		STATE:			A6
		ZIP:			K7A0A8
		BUSINESS PHONE:		855-558-9333

	MAIL ADDRESS:	
		STREET 1:		1 HERSHEY DRIVE
		CITY:			SMITH FALLS
		STATE:			A6
		ZIP:			K7A0A8
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>canopy6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></p>

<p style="font: 1pt/normal Times New Roman, Times, Serif; margin: 0 0 3pt">&nbsp;</p>

<p style="font: 18pt/normal Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"></p>

<!-- Field: Rule-Page --><div align="left" style="margin-top: 12pt; margin-bottom: 3pt"><div style="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font: 18pt/normal Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center">&nbsp;</p>

<p style="font: 18pt/normal Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center">&nbsp;</p>

<p style="font: 18pt/normal Times New Roman, Times, Serif; margin: 4pt 0 0; text-align: center"><b>UNITED STATES </b></p>

<p style="font: 18pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION
</b></p>

<p style="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Washington, D.C. 20549 </b></p>

<!-- Field: Rule-Page --><div align="left" style="margin: 1pt 1.7in"><div style="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font: 18pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><b>FORM&nbsp;6-K </b></p>

<!-- Field: Rule-Page --><div align="left" style="margin: 1pt 1.7in"><div style="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font: 12pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><b>REPORT OF FOREIGN ISSUER </b></p>

<p style="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>PURSUANT TO RULE 13a-16 OR 15d-16
</b></p>

<p style="font: 12pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>OF THE SECURITIES EXCHANGE ACT OF
1934 </b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><b>For the month of May 2019</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><b>Commission File No.&nbsp;001-38496</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><b>&nbsp;</b></p>

<!-- Field: Rule-Page --><div align="left" style="margin: 1pt 1.7in"><div style="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font: 24pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><b>Canopy Growth Corporation</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&nbsp;</b></p>

<!-- Field: Rule-Page --><div align="left" style="margin: 1pt 1.7in"><div style="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><b>1 Hershey Drive<br>
Smith Falls, Ontario<br>
K7A 0A8</b></p>

<p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&nbsp;</b></p>

<!-- Field: Rule-Page --><div align="left" style="margin: 1pt 1.7in"><div style="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0">Indicate by check mark whether the registrant files
or will file annual reports under cover Form&nbsp;20-F or Form&nbsp;40-F.</p>

<p style="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif">Form&nbsp;20-F&nbsp;&nbsp;</font><font style="font-family: Segoe UI Symbol,sans-serif">&#9744;</font>
<font style="font-family: Times New Roman, Times, Serif">Form 40-F&nbsp;&nbsp;</font><font style="font-family: Segoe UI Symbol,sans-serif">&#9746;</font></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0">Indicate by check mark if the registrant is submitting
the Form&nbsp;6-K in paper as permitted by Regulation S-T Rule&nbsp;101&nbsp;(b)&nbsp;(1):</p>

<p style="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;</font><font style="font-family: Segoe UI Symbol,sans-serif">&#9744;</font><font style="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;</font><font style="font-family: Segoe UI Symbol,sans-serif">&#9746;</font></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0">Indicate by check mark if the registrant is submitting
the Form&nbsp;6-K in paper as permitted by Regulation S-T Rule&nbsp;101&nbsp;(b)&nbsp;(7):</p>

<p style="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;</font><font style="font-family: Segoe UI Symbol,sans-serif">&#9744;</font><font style="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;</font><font style="font-family: Segoe UI Symbol,sans-serif">&#9746;</font></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0">Indicate by check mark whether the registrant by furnishing
the information contained in this Form&nbsp;is also thereby furnishing the information to the Commission pursuant to Rule&nbsp;12g3-2(b)&nbsp;under
the Securities Exchange Act of 1934.</p>

<p style="font: 10pt/normal Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"><font style="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;</font><font style="font-family: Segoe UI Symbol,sans-serif">&#9744;</font><font style="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;</font><font style="font-family: Segoe UI Symbol,sans-serif">&#9746;</font>
<font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 1pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<!-- Field: Rule-Page --><div align="left" style="margin-top: 3pt; margin-bottom: 12pt"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 4pt solid; width: 100%">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"></DIV>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&nbsp;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>EXHIBIT INDEX </b></p>

<p style="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr>
    <td style="width: 8%">&nbsp;</td>
    <td style="width: 2%">&nbsp;</td>
    <td style="width: 90%">&nbsp;</td></tr>
<tr>
    <td style="font: 11pt/107% Calibri, Helvetica, Sans-Serif">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="font: 11pt/107% Calibri, Helvetica, Sans-Serif">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td nowrap>
        <p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Exhibit</b></p>
<!-- Field: Rule-Page --><div align="left" style="margin-top: 1pt; margin-bottom: 1pt"><div style="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</div></div><!-- Field: /Rule-Page --></td>
    <td>&nbsp;</td>
    <td nowrap>
        <p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0"><b>Description</b></p>
<!-- Field: Rule-Page --><div align="left" style="margin-top: 1pt; margin-bottom: 1pt"><div style="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr>
<tr style="vertical-align: top">
    <td nowrap style="font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><A HREF="ex991.htm">99.1</A></FONT></td>
    <td><FONT STYLE="color: Black">&nbsp;</FONT></td>
    <td style="font: 11pt/107% Calibri, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><A HREF="ex991.htm">Press
    Release - Canopy Growth Introduces Spectrum Therapeutics</A></FONT></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center">1</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center">&nbsp;</p>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"></DIV>
    <!-- Field: /Page -->

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center">&nbsp;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0">Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0">&nbsp;&nbsp;</p>

<p style="font: 12pt/normal Times New Roman, Times, Serif; margin: 0"><u></u></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr>
    <td style="width: 50%">&nbsp;</td>
    <td style="width: 7%">&nbsp;</td>
    <td style="width: 43%">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="font: 11pt/107% Calibri, Helvetica, Sans-Serif">&nbsp;</td>
    <td style="font: 11pt/107% Calibri, Helvetica, Sans-Serif">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td colspan="2" style="font: 11pt/107% Calibri, Helvetica, Sans-Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canopy Growth Corporation</font></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td colspan="2" style="font: 11pt/107% Calibri, Helvetica, Sans-Serif">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="font: 11pt/107% Calibri, Helvetica, Sans-Serif">&nbsp;</td>
    <td style="font: 11pt/107% Calibri, Helvetica, Sans-Serif">&nbsp;</td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top; font: 11pt/107% Calibri, Helvetica, Sans-Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</font></td>
    <td style="vertical-align: bottom">
        <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">/s/ Bruce Linton</p>
<!-- Field: Rule-Page --><div align="left" style="margin-top: 1pt; margin-bottom: 1pt"><div style="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</div></div><!-- Field: /Rule-Page --></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top; font: 11pt/107% Calibri, Helvetica, Sans-Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</font></td>
    <td style="vertical-align: bottom; font: 11pt/107% Calibri, Helvetica, Sans-Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bruce Linton</font></td></tr>
<tr>
    <td>&nbsp;</td>
    <td style="vertical-align: top; font: 11pt/107% Calibri, Helvetica, Sans-Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</font></td>
    <td style="vertical-align: bottom; font: 11pt/107% Calibri, Helvetica, Sans-Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</font></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0">Date: May 7, 2019</p>

<p style="font: 1pt/normal Times New Roman, Times, Serif; margin: 0.25in 0 0"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center">2</p>




<p style="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991.htm
<DESCRIPTION>NEWS RELEASE DATED MAY 7, 2019
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><B>Exhibit 99.1</B></FONT></P>

<P STYLE="margin: 0; text-align: right"></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"></P>

<P STYLE="font: bold 24pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">&nbsp;<IMG SRC="image_002.jpg" ALT="Canopy Growth Introduces Spectrum Therapeutics (CNW Group|Canopy Growth Corporation)" STYLE="height: 99px; width: 197px"></P>

<P STYLE="font: bold 24pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Canopy Growth Introduces Spectrum Therapeutics</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">SMITHS FALLS, ON, May 7, 2019 /CNW/ -&nbsp;Canopy
Growth Corporation (&quot;Canopy Growth&quot; or the &quot;Company&quot;) (TSX: WEED) (NYSE: CGC) is pleased to introduce Spectrum
Therapeutics, a new global brand that will encompass all of the Company's ongoing commercial medical and clinical research operations
including Spectrum Cannabis, Canopy Health Innovations (CHI), and the most recent addition to Canopy Growth's medical portfolio,
Bionorica SE-founded C<SUP>3</SUP> Cannabinoid Compound Company (&quot;C<SUP>3</SUP>&quot;), a European leader in cannabinoid-based
medical therapies.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Incorporating these entities into one unified
ecosystem will integrate the Company's medical efforts as one global healthcare enterprise. Spectrum Therapeutics now encompasses
the production and distribution of full-spectrum and single cannabinoid medical cannabis products; industry-leading education,
resources and support for patients and healthcare practitioners; as well as pre-clinical and clinical research and the development
of cannabinoid-based medicines.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">The recent acquisition of C<SUP>3</SUP> will
allow Spectrum Therapeutics to continue to advance leadership in medical cannabis globally by further expanding its ability to
empower physicians in Europe and around the world with the knowledge and therapies drawn from a full range of cannabinoid-based
medicines. This includes dronabinol, C<SUP>3</SUP>'s cannabinoid pharmaceutical drug available in Germany, Austria, Switzerland,
and Denmark. Dronabinol, while integrated into the Spectrum Therapeutics commercial offering, will continue to be marketed under
C<SUP>3</SUP>'s established and recognized branding, Bionorica Ethics.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">&quot;We've always been a company that provides
more than medical cannabis to our patients,&quot; commented Dr. Mark Ware, Chief Medical Officer, Canopy Growth. &quot;We also
offer education for patients and healthcare professionals and are engaged in research to define the safety and efficacy of cannabinoid
medicines and the development of new cannabinoid-based treatments. Integrating our commercial medical businesses and clinical research
arm under a single entity better reflects our position as a healthcare company that's driving further acceptance of cannabinoids
as mainstream medicine and addressing the medical and wellness needs of our patients worldwide.&quot;</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">In addition to providing commercially available
medical cannabis products on five continents, Spectrum Therapeutics will continue to offer medical cannabis education for patients
and healthcare professionals in countries with legal regulatory frameworks. Through the continuation of CHI and C<SUP>3</SUP>'s
respective clinical research programs, Spectrum Therapeutics will also focus on the research and development of clinically ready
cannabinoid drug formulations and dosage formats. In addition to supporting drug registration, this research also support's best-in-class
physician and patient interaction and education for Spectrum Therapeutics' commercial operations on a global basis.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"><B>Entities now under the Spectrum Therapeutics
banner include:</B></P>

<UL STYLE="list-style-type: disc">

<LI STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"><B>Spectrum Cannabis:</B> Known for its colour-coded spectrum
to categorize medical cannabis according to THC and CBD levels, the commercial medical arm of the Company operates in 12 countries
including Australia, Brazil, Canada, Chile, Colombia, Czech Republic, Denmark, Germany, Lesotho, Peru, Poland, and the United Kingdom.
In Canada alone, the team has conducted 61,000+ healthcare professional visits.</LI>

<LI STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"><B>Canopy Health Innovations (CHI):</B> With 38 provisional
patents filed in the US designed to address a range of medical issues, from addiction to pain management, Canopy Health Innovations
continues to build a robust portfolio of IP, pre-clinical and clinical evidence to support cannabis-based medicines that deliver
therapeutic value in areas of unmet medical need. Additionally, across five continents, CHI has 11 ongoing and planned therapeutic
trials and another 11 third-party investigator-initiated trials supported by Spectrum Therapeutics. More than 900 patients will
be enrolled in research trials testing the efficacy of cannabinoid-based therapies and more than 1800 patients are participating
in the EQUAL program (Evaluation of Quality of Life) that will investigate the quality of life of patients before and after treatment
with medical cannabis.</LI>

<LI STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt"><B>C<SUP>3</SUP> Cannabinoid Compound Company (C<SUP>3</SUP>):</B>&nbsp;C<SUP>3</SUP>
is Europe's largest cannabinoid-based pharmaceuticals company. The company was founded in 2014 by Bionorica SE, one of the world's
leading producers of herbal medicines, as a holding company for the companies Bionorica ethics and THC Pharm. Both Bionorica ethics
and THC Pharm have for almost two decades been researching and developing the key therapeutic ingredients of the cannabis flower:
tetrahydrocannabinol (THC) and cannabidiol (CBD). One of the most significant of C<SUP>3</SUP>'s medical offerings is dronabinol,
a pure chemical compound with standardized concentrations of THC that can be prescribed by doctors in Germany for any type of chronic
pain and for any condition in palliative care. &nbsp;</LI>

</UL>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Here's to Future (Therapeutic) Growth.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"><B>About Canopy Growth Corporation</B><BR>
Canopy Growth (TSX:WEED, NYSE:CGC) is a world-leading diversified cannabis, hemp and cannabis device company, offering distinct
brands and curated cannabis varieties in dried, oil and Softgel capsule forms, as well as medical devices through the Company's
subsidiary, Storz &amp; Bickel GMbH &amp; Co. KG. From product and process innovation to market execution, Canopy Growth is driven
by a passion for leadership and a commitment to building a world-class cannabis company one product, site and country at a time.
The Company has operations in over a dozen countries across five continents.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">The Company's medical division, Spectrum Therapeutics
is proudly dedicated to educating healthcare practitioners, conducting robust clinical research, and furthering the public's understanding
of cannabis, and has devoted millions of dollars toward cutting edge, commercializable research and IP development. Spectrum Therapeutics
sells a range of full-spectrum products using its colour-coded classification Spectrum system as well as single cannabinoid Dronabinol
under the brand Bionorica Ethics.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">The Company operates retail stores across Canada
under its award-winning Tweed and Tokyo Smoke banners. Tweed is a globally recognized cannabis brand which has built a large and
loyal following by focusing on quality products and meaningful customer relationships.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">From our historic public listing on the Toronto
Stock Exchange and New York Stock Exchange to our continued international expansion, pride in advancing shareholder value through
leadership is engrained in all we do at Canopy Growth. Canopy Growth has established partnerships with leading sector names including
cannabis icons Snoop Dogg and Seth Rogen, breeding legends DNA Genetics and Green House Seeds, Battelle, the world's largest nonprofit
research and development organization, and Fortune 500 alcohol leader Constellation Brands, to name but a few. Canopy Growth operates
ten licensed cannabis production sites with over 4.4 million square feet of production capacity, including over one million square
feet of GMP certified production space. For more information visit www.canopygrowth.com</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"><B>Notice Regarding Forward Looking Statements</B><BR>
This news release contains &quot;forward-looking statements&quot; within the meaning of the United States Private Securities Litigation
Reform Act of 1995 and &quot;forward-looking information&quot; within the meaning of applicable Canadian securities legislation.
Often, but not always, forward-looking statements and information can be identified by the use of words such as &quot;plans&quot;,
&quot;expects&quot; or &quot;does not expect&quot;, &quot;is expected&quot;, &quot;estimates&quot;, &quot;intends&quot;, &quot;anticipates&quot;
or &quot;does not anticipate&quot;, or &quot;believes&quot;, or variations of such words and phrases or state that certain actions,
events or results &quot;may&quot;, &quot;could&quot;, &quot;would&quot;, &quot;might&quot; or &quot;will&quot; be taken, occur
or be achieved. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors which
may cause the actual results, performance or achievements of Canopy Growth or its subsidiaries to be materially different from
any future results, performance or achievements expressed or implied by the forward-looking statements or information contained
in this news release. Examples of such statements include &quot;industry-leading education, resources and support for patients&quot;,
and &quot;ongoing clinical research programs which are expected to complement Spectrum Therapeutics'&quot; . Risks, uncertainties
and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities
to differ materially from those expressed or implied by such forward-looking information, including clinical trial work, and such
risks contained in the Company's annual information form dated June 27, 2018 and filed with Canadian securities regulators available
on the Company's issuer profile on SEDAR at www.sedar.com. Although the Company believes that the assumptions and factors used
in preparing the forward-looking information or forward-looking statements in this news release are reasonable, undue reliance
should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames
or at all. The forward-looking information and forward-looking statements included in this news release are made as of the date
of this news release and the Company does not undertake an obligation to publicly update such forward-looking information or forward-looking
information to reflect new information, subsequent events or otherwise unless required by applicable securities law.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">&nbsp;</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">View original content to download multimedia:http://www.prnewswire.com/news-releases/canopy-growth-introduces-spectrum-therapeutics-300845202.html</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">SOURCE Canopy Growth Corporation</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">View original content to download multimedia:
http://www.newswire.ca/en/releases/archive/May2019/07/c7684.html</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">%CIK: 0001737927</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin: 0"><B>For further information: </B>Caitlin O'Hara, Media Relations,
Caitlin.Ohara@canopygrowth.com, 613-291-3239; Investor Relations, Tyler Burns, Tyler.Burns@canopygrowth.com, 855-558-9333 ext.
122</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">CO: Canopy Growth Corporation</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">CNW 08:30e 07-MAY-19</P>



<P STYLE="font: bold 24pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"></P>



<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"></p>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !C ,4# 2(  A$! Q$!_\0
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I%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
